{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:56:34Z","timestamp":1792637794408,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajp.2026.104983","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:27:44Z","timestamp":1776468464000},"page":"104983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-4237","authenticated-orcid":false,"given":"Fabiola","family":"Raffone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6684-7689","authenticated-orcid":false,"given":"Filippo","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2991-3032","authenticated-orcid":false,"given":"Arianna","family":"De Ciechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaja","family":"Girone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-5897","authenticated-orcid":false,"given":"Monica","family":"Macellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-0539","authenticated-orcid":false,"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-1000","authenticated-orcid":false,"given":"Vassilis","family":"Martiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2026.104983_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067194","article-title":"Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial","volume":"376","author":"Abbar","year":"2022","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ajp.2026.104983_bib2","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1017\/S0033291714003079","article-title":"Impulsivity in borderline personality disorder","volume":"45","author":"Barker","year":"2015","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.ajp.2026.104983_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior","volume":"41","author":"Canuso","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2026.104983_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2026.104983_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1394787","article-title":"Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review","volume":"15","author":"Di Vincenzo","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"6103","key":"10.1016\/j.ajp.2026.104983_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ajp.2026.104983_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.ajp.2026.104983_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2026.104983_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1588902","article-title":"Treatment-resistant depression: from clinical burden to precision therapeutics","volume":"16","author":"Fiorillo","year":"2025","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2026.104983_bib10","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2026.104983_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress Anxiety"},{"issue":"4","key":"10.1016\/j.ajp.2026.104983_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1012779403943","article-title":"Measurement of deliberate self-harm: preliminary data on the Deliberate Self-Harm Inventory","volume":"23","author":"Gratz","year":"2001","journal-title":"J. Psychopathol. Behav. Assess."},{"issue":"5","key":"10.1016\/j.ajp.2026.104983_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9389","article-title":"Association of borderline personality disorder criteria with suicide attempts among US adults","volume":"4","author":"Grilo","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1\u20133","key":"10.1016\/j.ajp.2026.104983_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jad.2013.01.004","article-title":"Risk factors for suicide in individuals with depression: a systematic review","volume":"147","author":"Hawton","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.ajp.2026.104983_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicidal ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2026.104983_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1521\/ijct.2015.8.2.114","article-title":"The three-step theory (3ST): a new theory of suicide rooted in the ideation-to-action framework","volume":"8","author":"Klonsky","year":"2015","journal-title":"Int. J. Cogn. Ther."},{"key":"10.1016\/j.ajp.2026.104983_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.genhosppsych.2025.04.005","article-title":"Suicide-related outcomes in borderline personality disorder: a systematic review and meta-analysis","author":"Lak","year":"2025","journal-title":"Gen. Hosp. Psychiatry 93 101109."},{"issue":"9759","key":"10.1016\/j.ajp.2026.104983_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(10)61422-5","article-title":"Borderline personality disorder","volume":"377","author":"Leichsenring","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajp.2026.104983_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamapsychiatry.2014.3039","article-title":"Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial","volume":"72","author":"Linehan","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2026.104983_bib20","doi-asserted-by":"crossref","DOI":"10.2174\/011570159X392347250929114024","article-title":"Gender differences in suicidal and self-harming responses to esketamine: a real-world retrospective study","author":"Martiadis","year":"2025","journal-title":"Curr. Neuropharmacol. (Online Print. )."},{"key":"10.1016\/j.ajp.2026.104983_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.ajp.2026.104983_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11920-023-01440-w","article-title":"Suicide risk in personality disorders: a systematic review","volume":"25","author":"McClelland","year":"2023","journal-title":"Curr. Psychiatry Rep."},{"issue":"3","key":"10.1016\/j.ajp.2026.104983_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ajp.2026.104983_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104351","article-title":"Ketamine: An emerging agent in the management of neuropsychiatric disorders","volume":"106","author":"Menke","year":"2025","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.ajp.2026.104983_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev.clinpsy.121208.131258","article-title":"Self-injury","volume":"6","author":"Nock","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"1754","key":"10.1016\/j.ajp.2026.104983_bib26","article-title":"The integrated motivational\u2013volitional model of suicidal behaviour","volume":"373","author":"O\u2019Connor","year":"2018","journal-title":"Philos. Trans. R. Soc. B"},{"key":"10.1016\/j.ajp.2026.104983_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1736114","article-title":"Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality","volume":"16","author":"Olivola","year":"2026","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2026.104983_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ps.53.6.738","article-title":"Chronic suicidality among patients with borderline personality disorder","volume":"53","author":"Paris","year":"2002","journal-title":"Psychiatr. Serv."},{"issue":"6","key":"10.1016\/j.ajp.2026.104983_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt Impulsiveness Scale","volume":"51","author":"Patton","year":"1995","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.ajp.2026.104983_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104344","article-title":"Systematic review of parenteral ketamine for managing acute agitation in emergency settings","volume":"103","author":"Peter","year":"2025","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.ajp.2026.104983_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hup.70008","article-title":"Efficacy of intranasal esketamine in treatment-resistant depression: a 6-month real-world study","volume":"40","author":"Pompili","year":"2025","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"6","key":"10.1016\/j.ajp.2026.104983_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.ajp.2026.104983_bib33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2026.104983_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/011570159X337670241029062524","article-title":"Esketamine treatment trajectory of patients with treatment-resistant depression in the mid and long-term run: data from REAL-ESK Study Group","volume":"23","author":"Rosso","year":"2025","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.ajp.2026.104983_bib35","first-page":"352","article-title":"Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme","volume":"26","author":"Samalin","year":"2022","journal-title":"Int. J. Psychiatry Clin. Pr."},{"issue":"10","key":"10.1016\/j.ajp.2026.104983_bib36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of esketamine nasal spray: a comprehensive analysis almost 5 years after first approval","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104983_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2025.104413","article-title":"Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial","volume":"106","author":"Seraj","year":"2025","journal-title":"Asian J. Psychiatr."},{"issue":"3","key":"10.1016\/j.ajp.2026.104983_bib38","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2026.104983_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2026.104983_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2020.3598","article-title":"Association of borderline personality disorder criteria with prospectively observed suicide attempts: findings from the Collaborative Longitudinal Study of Personality Disorders over 10 years of follow-up","volume":"78","author":"Yen","year":"2021","journal-title":"JAMA Psychiatry"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201826001565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201826001565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:31:07Z","timestamp":1779679867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201826001565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S1876201826001565"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2026.104983","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2026.104983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104983"}}